Host response to Chikungunya virus and perspectives for immune-based therapies

Future Virology

Volumn 6, Issue 8, 2011, Pages 975-984

  Teng, Terk Shin ^a   Kam, Yiu Wing ^a   Tan, Jeslin Jl ^a   Ng, Lisa Fp ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

alphavirus; chikungunya; control strategies; epidemiology; host response; immunity; infection; interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; VIRUS LIKE PARTICLE VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ARTHRALGIA; BACKACHE; BLEEDING; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CYTOKINE PRODUCTION; ENDOSOME; GENE REPLICATION; HOST PATHOGEN INTERACTION; HUMAN; HYPOCALCEMIA; INFECTION CONTROL; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; LYMPHOCYTOPENIA; MENINGOENCEPHALITIS; MYASTHENIA; MYOCARDITIS; NAUSEA AND VOMITING; NONHUMAN; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS INFECTIVITY; VIRUS PATHOGENESIS; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ALPHAVIRUS; CHIKUNGUNYA VIRUS;

EID: 80051997232     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.67     Document Type: Review

References (88)

1. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol. Mol. Biol. Rev. 58(3), 491-562 (1994).
2. Solignat M, Gay B, Higgs S, Briant L, Devaux C. Replication cycle of chikungunya: a re-emerging arbovirus. Virology 393(2), 183-197 (2009).
3. Voss JE, Vaney MC, Duquerroy S et al. Glycoprotein organization of chikungunya virus particles revealed by x-ray crystallography. Nature 468(7324), 709-712 (2010).
4. Her Z, Kam YW, Lin RT, Ng LF. Chikungunya: a bending reality. Microb. Infect. 11(14-15), 1165-1176 (2009).
5. Lumsden WHR. An epidemic of virus disease in southern province, Tanganyika territory, in 1952-1953 II. General description and epidemiology. Trans. R. Soc. Trop. Med. Hyg. 49(1), 33-57 (1955).
6. Robinson MC. An epidemic of virus disease in southern province, Tanganyika territory, in 1952-1953. Trans. R. Soc. Trop. Med. Hyg. 49(1), 28-32 (1955).
7. Powers AM, Logue CH. Changing patterns of Chikungunya virus: re-emergence of a zoonotic arbovirus. J. Gen. Virol. 88(9), 2363-2377 (2007).
8. Sergon K, Njuguna C, Kalani R et al. Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am. J. Trop. Med. Hyg. 78(2), 333-337 (2008).
9. Outbreak and spread of Chikungunya. Wkly Epidemiol. Rec. 82(47), 409-415 (2007).
10. Schuffenecker I, Iteman I, Michault A et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3(7), E263 (2006).
11. Hochedez P, Jaureguiberry S, Debruyne M et al. Chikungunya infection in travelers. Emerg. Infect. Dis. 12(10), 1565-1567 (2006).
12. Tandale BV, Sathe PS, Arankalle VA et al. Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. J. Clin. Virol. 46(2), 145-149 (2009).
13. Theamboonlers A, Rianthavorn P, Praianantathavorn K, Wuttirattanakowit N, Poovorawan Y. Clinical and molecular characterization of Chikungunya virus in South Thailand. Jpn J. Infect. Dis. 62(4), 303-305 (2009).
14. Sam IC, Kamarulzaman A, Ong GS et al. Chikungunya virus-associated death in Malaysia. Trop. Biomed. 27(2), 343-347 (2010).
15. Rezza G, Nicoletti L, Angelini R et al. Infection with Chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370(9602), 1840-1846 (2007).
16. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Path. 4(12), E201 (2007).
17. Ryman KD, Klimstra WB. Host responses to alphavirus infection. Immunol. Rev. 225, 27-45 (2008).
18. Couderc T, Chrétien F, Schilte C et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 4(2), E29 (2008).
19. Gardner J, Anraku I, Le TT et al. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84(16), 8021-8032 (2010).
20. Labadie K, Larcher T, Joubert C et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 120(3), 894-906 (2010).
21. Morrison TE, Oko L, Montgomery SA et al. A mouse model of Chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am. J. Pathol. 178(1), 32-40 (2011).
22. Chow A, Her Z, Ong EKS et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J. Infect. Dis. 203(2), 149-157 (2010).
23. Ng LFP, Chow A, Sun YJ et al. IL-1b, IL-6, and RANTES as biomarkers of chikungunya severity. PLoS One 4(1), E4261 (2009).
24. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino Al, Leroy EM. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J. Infect. Dis. 204(1), 115-123 (2011).
25. Deller LCJJ Jr, Russell LCPK. Chikungunya disease. Am. J. Trop. Med. Hyg. 17(1), 107-111 (1968).
26. Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection. A retrospective study of 107 cases. S. Afr. Med. J. 63(9), 313-315 (1983).
27. Borgherini G, Poubeau P, Staikowsky F et al. Outbreak of Chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin. Infect. Dis. 44(11), 1401-1407 (2007).
28. Brighton SW. Chikungunya virus infections. S. Afr. Med. J. 59(16), 552 (1981).
29. Das T, Jaffar-Bandjee MC, Hoarau JJ et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog. Neurobiol. 91(2), 121-129 (2010).
30. Lemant J, Boisson V, Winer A et al. Serious acute Chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit. Care Med. 36(9), 2536-2541 (2008).
31. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin. Infect. Dis. 49(6), 942-948 (2009).
32. Josseran L, Paquet C, Zehgnoun A et al. Chikungunya disease outbreak, Reunion Island. Emerg. Infect. Dis. 12, 1994-1995 (2006).
33. Schilte C, Couderc T, Chretien F et al. Type I IFN controls Chikungunya virus via its action on nonhematopoietic cells. J. Exp. Med. 207(2), 429-442 (2010).
34. Sourisseau M, Schilte C, Casartelli N et al. Characterization of reemerging chikungunya virus. PLoS Pathog. 3(6), E89 (2007).
35. Her Z, Malleret B, Chan M et al. Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J. Immunol. 184(10), 5903-5913 (2010).
36. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J. Immunol. 184(10), 5914-5927 (2010).
37. Flexman JP, Smith DW, Mackenzie JS et al. A comparison of the diseases caused by Ross River virus and Barmah forest virus. Med. J. Aust. 169(3), 159-163 (1998).
38. Jacups SP, Whelan PI, Currie BJ. Ross River virus and Barmah forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia. Vector Borne Zoonotic Dis. 8(2), 283-297 (2008).
39. Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J. Virol. 80(2), 737-749 (2006).
40. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149(2), 217-225 (2007).
41. Schaible HG, von Banchet GS, Boettger MK et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann. NY Acad. Sci. 1193, 60-69 (2010).
42. Binn LN, Harrison VR, Randall R. Patterns of viremia and antibody observed in rhesus monkeys inoculated with Chikungunya and other serologically related group arboviruses. Am. J. Trop. Med. Hyg. 16(6), 782-785 (1967).
43. Harrison VR, Binn LN, Randall R. Comparative immunogenicities of Chikungunya vaccines prepared in avian and mammalian tissues. Am. J. Trop. Med. Hyg. 16(6), 786-791 (1967).
44. Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol. 77(22), 12022-12032 (2003).
45. Klimstra WB, Ryman KD, Johnston RE. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 72(9), 7357-7366 (1998).
46. Kielian M, Klimjack MR, Ghosh S, Duffus WA. Mechanisms of mutations inhibiting fusion and infection by Semliki forest virus. J. Cell Biol. 134(4), 863-872 (1996).
47. Ahn A, Schoepp RJ, Sternberg D, Kielian M. Growth and stability of a cholesterol-independent Semliki forest virus mutant in mosquitoes. Virology 262(2), 452-456 (1999).
48. Lu YE, Cassese T, Kielian M. The cholesterol requirement for Sindbis virus entry and exit and characterization of a spike protein region involved in cholesterol dependence. J. Virol. 73(5), 4272-4278 (1999).
49. Bernard E, Solignat M, Gay B et al. Endocytosis of Chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments. PLoS One 5(7), E11479 (2010).
50. Hahon N, Zimmerman WD. Chikungunya virus infection of cell monolayers by cell-to-cell and extracellular transmission. Appl. Microbiol. 19(2), 389-391 (1970).
51. Krejbich-Trotot P, Denizot M, Hoarau JJ, Jaffar-Bandjee MC, Das T, Gasque P. Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. FASEB J. 25(1), 314-325 (2011).
52. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
53. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 25(3), 373-381 (2006).
54. McCartney SA, Colonna M. Viral sensors: diversity in pathogen recognition. Immunol. Rev. 227(1), 87-94 (2009).
55. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 22(5), 561-569 (2006).
56. Honda K, Takaoka A, Taniguchi T. Type I Interferon gene induction by the interferon regulatory factor family of transcription tactors. Immunity 25(3), 349-360 (2006).
57. Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and Mda5- mediated type I interferon induction. Nat. Immunol. 6(10), 981-988 (2005).
58. Decker T, Stockinger S, Karaghiosoff M, Muller M, Kovarik P. IFNs and STATs in innate immunity to microorganisms. J. Clin. Invest. 109(10), 1271-1277 (2002).
59. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 12(2-3), 143-156 (2001).
60. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-a genes by positive feedback through interferon regulatory factor-7. EMBO J. 17(22), 6660-6669 (1998).
61. Fros JJ, Liu WJ, Prow NA et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J. Virol. 84(20), 10877-10887 (2010).
62. White LK, Sali T, Alvarado D et al. Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. J. Virol. 85(1), 606-620 (2011).
63. Brehin AC, Casademont I, Frenkiel MP, Julier C, Sakuntabhai A, Despres P. The large form of human 2′,5′-oligoadenylate synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology 384(1), 216-222 (2009).
64. Cline MS, Smoot M, Cerami E et al. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2(10), 2366-2382 (2007).
65. Ramirez F, Schlicker A, Assenov Y, Lengauer T, Albrecht M. Computational analysis of human protein interaction networks. Proteomics 7(15), 2541-2552 (2007).
66. Couderc T, Khandoudi N, Grandadam M et al. Prophylaxis and therapy for Chikungunya virus infection. J. Infect. Dis. 200(4), 516-523 (2009).
67. Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J. Hyg. (Lond).54(2), 177-191 (1956).
68. Ivanov AP, Ivanova OE, Lomonosov NN, Pozdnyakov SV, Konstantinov OK, Bah MA. Serological investigations of Chikungunya virus in the Republic of Guinea. Ann. Soc. Belg. Med. Trop. 72(1), 73-74 (1992).
69. Osterrieth P, Deleplanque-Liegeois P, Renoirte R. Research on the chikungunya virus in the Belgian Congo. II. Serological investigation. Ann. Soc. Belg. Med. Trop. (1920) 40, 205-213 (1960).
70. Griffin D, Levine B, Tyor W, Ubol S, Despres P. The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159, 155-161 (1997).
71. Akahata W, Yang ZY, Andersen H et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16(3), 334-338 (2010).
72. Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG. Structural changes of envelope proteins during alphavirus fusion. Nature 468(7324), 705-708 (2010).
73. Brighton SW. Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study. S. Afr. Med. J. 66(6), 217-218 (1984).
74. De Lamballerie X, Boisson V, Reynier JC et al. On Chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis. 8(6), 837-839 (2008).
75. Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM. In vitro inhibition of Chikungunya and Semliki forest viruses replication by antiviral compounds: synergistic effect of interferon-a and ribavirin combination. Antiviral Res. 61(2), 111-117 (2004).
76. Li Y, Wang L, Li S et al. Seco-pregnane steroids target the subgenomic RNA of alphavirus-like RNA viruses. Proc. Natl Acad. Sci. USA 104(19), 8083-8088 (2007).
77. Eckels KH, Harrison VR, Hetrick FM. Chikungunya virus vaccine prepared by Tween-ether extraction. Appl. Microbiol. 19(2), 321-325 (1970).
78. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62(6), 681-685 (2000).
79. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed Chikungunya vaccine. J. Immunol. 107(3), 643-647 (1971).
80. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Lupton HW. Development of an attenuated strain of Chikungunya virus for use in vaccine production. Vaccine 4(3), 157-162 (1986).
81. Mallilankaraman K, Shedlock DJ, Bao H et al. A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl. Trop. Dis. 5(1), E928 (2011).
82. Muthumani K, Lankaraman KM, Laddy DJ et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 26(40), 5128-5134 (2008).
83. Partidos CD, Weger J, Brewoo J et al. Probing the attenuation and protective efficacy of a candidate Chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 29(16), 3067-3073 (2011).
84. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27(18), 2513-2522 (2009).
85. Wang E, Volkova E, Adams AP et al. Chimeric alphavirus vaccine candidates for Chikungunya. Vaccine 26(39), 5030-5039 (2008).
86. White A, Berman S, Lowenthal JP. Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl. Microbiol. 23(5), 951-952 (1972).
87. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13(4), 602-614 (2000).
88. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 47(2), 57-77 (2000).